Associations Between miRNAs and Two Different Cancers: Breast and Colon

References

• Baeyens-Fernández JA, Molina-Portillo E, Pollán M, et al. Trends in incidence, mortality and survival in women with breast cancer from 1985 to 2012 in Granada, Spain: a population-based study. BMC Cancer. 2018;18(1):781. doi:10.1186/s12885-018-4682-130068302
   PubMedGoogle Scholar
• WHO. Breast Cancer: Prevention and Control. WHO; 2016 Available from: https://www.who.int/cancer/detection/breastcancer/en/index2.html. Accessed 114, 2019.
   Google Scholar
• PDQ Screening and Prevention Editorial Board. Colorectal Cancer Prevention (PDQ®): patient Version; 2002 Available from: http://www.ncbi.nlm.nih.gov/pubmed/26389376. Accessed 114, 2019.
   Google Scholar
• Zhang L, Xu Y, Jin X, et al. A circulating miRNA signature as a diagnostic biomarker for non-invasive early detection of breast cancer. Breast Cancer Res Treat. 2015;154:423–434. doi:10.1007/s10549-015-3591-026476723
   PubMed Web of Science ®Google Scholar
• Felekkis K, Touvana E, Stefanou CH, Deltas C. microRNAs: a newly described class of encoded molecules that play a role in health and disease. Hippokratia. 2010;14(4):236.21311629
   PubMed Web of Science ®Google Scholar
• Zhang Y, Lin C, Liao G, et al. MicroRNA-506 suppresses tumor proliferation and metastasis in colon cancer by directly targeting the oncogene EZH2. Oncotarget. 2015;6:32586–32601. doi:10.18632/oncotarget.530926452129
   PubMedGoogle Scholar
• Tian Y, Pan Q, Shang Y, et al. MicroRNA-200 (miR-200) cluster regulation by achaete scute-like 2 (Ascl2): impact on the epithelial-mesenchymal transition in colon cancer cells. J Biol Chem. 2014;289:36101–36115. doi:10.1074/jbc.M114.59838325371200
   PubMed Web of Science ®Google Scholar
• Kanematsu S, Tanimoto K, Suzuki Y, Sugano S. Screening for possible miRNA-mRNA associations in a colon cancer cell line. Gene. 2014;533:520–531. doi:10.1016/j.gene.2013.08.00523939471
   PubMed Web of Science ®Google Scholar
• Al-Khanbashi M, Caramuta S, Alajmi AM, et al. Tissue and serum miRNA profile in Locally Advanced Breast Cancer (LABC) in Response to Neo-Adjuvant Chemotherapy (NAC) treatment. PLoS One. 2016;11:e0152032. doi:10.1371/journal.pone.015203227064979
   PubMed Web of Science ®Google Scholar
• Zhang C, Liu K, Li T, et al. miR-21: a gene of dual regulation in breast cancer. Int J Oncol. 2016;48:161–172. doi:10.3892/ijo.2015.323226549725
   PubMed Web of Science ®Google Scholar
• Luo LJ, Yang F, JJ D, et al. MiR-31 inhibits migration and invasion by targeting SATB2 in triple negative breast cancer. Gene. 2016;594:47–58. doi:10.1016/j.gene.2016.08.05727593563
   PubMed Web of Science ®Google Scholar
• Xia C, Yang Y, Kong F, Kong Q, Shan C. MiR-143-3p inhibits the proliferation, cell migration and invasion of human breast cancer cells by modulating the expression of MAPK7. Biochimie. 2018;147:98–104. doi:10.1016/j.biochi.2018.01.00329360495
   PubMed Web of Science ®Google Scholar
• Ding Y, Zhang C, Zhang J, et al. miR-145 inhibits proliferation and migration of breast cancer cells by directly or indirectly regulating TGF-beta1 expression. Int J Oncol. 2017;50:1701–1710. doi:10.3892/ijo.2017.394528393176
   PubMed Web of Science ®Google Scholar
• Li T, Luo W, Liu K, Li X, Xi T. miR-31 promotes proliferation of colon cancer cells by targeting E2F2. Biotechnol Lett. 2015;37:523–532. doi:10.1007/s10529-014-1715-y25362258
   PubMed Web of Science ®Google Scholar
• Li C, Zhao L, Chen Y, et al. MicroRNA-21 promotes proliferation, migration, and invasion of colorectal cancer, and tumor growth associated with down-regulation of sec23a expression. BMC Cancer. 2016;16:605. doi:10.1186/s12885-016-2628-z27495250
   PubMed Web of Science ®Google Scholar
• Yu Y, Nangia-Makker P, Farhana L, Rajendra SG, Levi E, Majumdar AP. miR-21 and miR-145 cooperation in the regulation of colon cancer stem cells. Mol Cancer. 2015;14:98. doi:10.1186/s12943-015-0372-725928322
   PubMed Web of Science ®Google Scholar
• Edge, S.B. & Compton, C.C. Ann Surg Oncol (2010) 17: 1471 10.1245/s10434-010-0985-4
   Google Scholar
• Malati T. Tumour markers: an overview. Indian J Clin Biochem. 2007;22(2):17–31. doi:10.1007/BF0291330823105677
   PubMedGoogle Scholar
• GE Healthcare. Isolation of Mononuclear Cells Methodology and Applications. Available from: https://www.sigmaaldrich.com/content/dam/sigma-aldrich/docs/Sigma-Aldrich/General_Information/1/ge-isolation-of-mononuclear-cells.pdf. Accessed February 4, 2020.
   Google Scholar
• Berber U, Yilmaz I, Narli G, Haholu A, Kucukodaci Z, Demirel D. miR-205 and miR-200c: predictive micro RNAs for lymph node metastasis in triple negative breast cancer. J Breast Cancer. 2014;17:143–148. doi:10.4048/jbc.2014.17.2.14325013435
   PubMed Web of Science ®Google Scholar
• Chan JA, Krichevsky AM, Kosik KS, Krichevsky AM, Kosik KS. microRNA-21 is an antiapoptotic factor in human glioblastoma cells. Cancer Res. 2005;65:6029–6033. doi:10.1158/0008-5472.CAN-05-013716024602
   PubMed Web of Science ®Google Scholar
• Yan LX, Huang XF, Shao Q, et al. MicroRNA miR-21 overexpression in human breast cancer is associated with the advanced clinical stage, lymph node metastasis, and poor patient prognosis. RNA. 2008;14:2348–2360. doi:10.1261/rna.103480818812439
   PubMed Web of Science ®Google Scholar
• Iyevleva AG, Kuligina E, Mitiushkina NV, Togo AV, Miki Y, Imyanitov EN. High level of miR-21, miR-10b, and miR-31 expression in bilateral vs. unilateral breast carcinomas. Breast Cancer Res Treat. 2012;131:1049–1059. doi:10.1007/s10549-011-1845-z22057972
   PubMed Web of Science ®Google Scholar
• Hafez MM, Hassan ZK, Zekri AR, et al. MicroRNAs and metastasis-related gene expression in Egyptian breast cancer patients. Asian Pac J Cancer Prev. 2012;13:591–598. doi:10.7314/APJCP.2012.13.2.59122524830
   PubMed Web of Science ®Google Scholar
• De Mattos-arruda L, Bottai G, Nuciforo PG, et al. MicroRNA-21 links epithelial-to-mesenchymal transition and inflammatory signals to confer resistance to neoadjuvant trastuzumab and chemotherapy in HER2-positive breast cancer patients. Oncotarget. 2015;6:37269–37280. doi:10.18632/oncotarget.v6i3526452030
   PubMed Web of Science ®Google Scholar
• Jinling W, Sijing S, Jie Z, Guinean W. Prognostic value of circulating microRNA-21 for breast cancer: a systematic review and meta-analysis. Artif Cells Nanomed Biotechnol. 2017;45:1–6. doi:10.1080/21691401.2016.1216856
   PubMed Web of Science ®Google Scholar
• Yadav P, Mirza M, Nandi K, et al. Serum microRNA-21 expression as a prognostic and therapeutic biomarker for breast cancer patients. Tumour Biol. 2016;37:15275–15282. doi:10.1007/s13277-016-5361-y27696295
   PubMedGoogle Scholar
• Li S, Yang X, Yang J, Zhen J, Zhang D. Serum microRNA-21 as a potential diagnostic biomarker for breast cancer: a systematic review and meta-analysis. Clin Exp Med. 2016;16:29–35. doi:10.1007/s10238-014-0332-325516467
   PubMed Web of Science ®Google Scholar
• Usmani A, Shoro AA, Memon Z, Hussain M, Rehman R. The diagnostic, prognostic and predictive value of microRNA-21 in breast cancer patients, their daughters, and healthy individuals. Am J Cancer Res. 2015;5:2484–2490.26396924
   PubMed Web of Science ®Google Scholar
• Wang G, Wang L, Sun S, Wu J, Wang Q. Quantitative measurement of serum microRNA-21 expression in relation to breast cancer metastasis in Chinese females. Ann Lab Med. 2015;35:226–232. doi:10.3343/alm.2015.35.2.22625729725
   PubMed Web of Science ®Google Scholar
• Shen L, Wan Z, Ma Y, et al. The clinical utility of microRNA-21 as a novel biomarker for diagnosing human cancers. Tumour Biol. 2015;36:1993–2005. doi:10.1007/s13277-014-2806-z25431259
   PubMed Web of Science ®Google Scholar
• Gao J, Zhang Q, Xu J, Guo L, Li X. Clinical significance of serum miR-21 in breast cancer compared with CA153 and CEA. Chin J Cancer Res. 2013;25:743–748. doi:10.3978/j.issn.1000-9604.2013.12.0424385703
   PubMed Web of Science ®Google Scholar
• Si H, Sun X, Chen Y, et al. Circulating microRNA-92a and microRNA-21 as novel minimally invasive biomarkers for primary breast cancer. J Cancer Res Clin Oncol. 2013;139:223–229.23052693
   PubMed Web of Science ®Google Scholar
• Wang B, Zhang Q. The expression and clinical significance of circulating microRNA-21 in the serum of five solid tumors. J Cancer Res Clin Oncol. 2012;138:1659–1666. doi:10.1007/s00432-012-1244-922638884
   PubMed Web of Science ®Google Scholar
• Asaga S, Kuo C, Nguyen T, Terpenning M, Giuliano AE, Hoon DS. Direct serum assay for microRNA-21 concentrations in early and advanced breast cancer. Clin Chem. 2011;57:84–91. doi:10.1373/clinchem.2010.15184521036945
   PubMed Web of Science ®Google Scholar
• Knudsen KN, Nielsen BS, Lindebjerg J, Hansen TF, Holst R, Sorensen FB. microRNA-17 is the most up-regulated member of the miR-17-92 cluster during early colon cancer evolution. PLoS One. 2015;10:e0140503. doi:10.1371/journal.pone.014050326465597
   PubMed Web of Science ®Google Scholar
• Schetter AJ, Okayama H, Harris CC. The role of microRNAs in colorectal cancer. Cancer J. 2012;18:244–252. doi:10.1097/PPO.0b013e318258b78f22647361
   PubMed Web of Science ®Google Scholar
• Link A, Balaguer F, Shen Y, et al. Fecal MicroRNAs as novel biomarkers for colon cancer screening. Cancer Epidemiol Biomarkers Prev. 2010;19:1766–1774. doi:10.1158/1055-9965.EPI-10-002720551304
   PubMed Web of Science ®Google Scholar
• Slaby O, Svoboda M, Fabian P, et al. Altered expression of miR-21, miR-31, miR-143 and miR-145 is related to clinicopathologic features of colorectal cancer. Oncology. 2007;72:397–402. doi:10.1159/00011348918196926
   PubMed Web of Science ®Google Scholar
• Eslamizadeh S, Heidari M, Agah S, et al. The role of microRNA signature as diagnostic biomarkers in different clinical stages of colorectal cancer. Cell J. 2018;20:220–230. doi:10.22074/cellj.2018.536629633600
   PubMed Web of Science ®Google Scholar
• Nielsen BS, Jorgensen S, Fog JU, et al. High levels of microRNA-21 in the stroma of colorectal cancers predict short disease-free survival in stage II colon cancer patients. Clin Exp Metastasis. 2011;28:27–38. doi:10.1007/s10585-010-9355-721069438
   PubMed Web of Science ®Google Scholar
• Kjaer-Frifeldt S, Hansen TF, Nielsen BS, et al. The prognostic importance of miR-21 in stage II colon cancer: a population-based study. Br J Cancer. 2012;107:1169–1174. doi:10.1038/bjc.2012.36523011541
   PubMed Web of Science ®Google Scholar
• Kang WK, Lee JK, Oh ST, Lee SH, Jung CK. Stromal expression of miR-21 in T3-4a colorectal cancer is an independent predictor of early tumor relapse. BMC Gastroenterol. 2015;15:2. doi:10.1186/s12876-015-0227-025609245
   PubMed Web of Science ®Google Scholar
• Gao W, Liu L, Xu J, et al. A systematic analysis of predicted MiR-31-targets identifies a diagnostic and prognostic signature for lung cancer. Biomed Pharmacother. 2014;68(4):419–427. doi:10.1016/j.biopha.2014.03.00924726065
   PubMed Web of Science ®Google Scholar
• Yang X, Xu X, Zhu J, et al. miR-31 affects colorectal cancer cells by inhibiting autophagy in cancer-associated fibroblasts. Oncotarget. 2016;7(48):79617. doi:10.18632/oncotarget.v7i4827793031
   PubMedGoogle Scholar
• Ouyang M, Li Y, Ye S, et al. MicroRNA profiling implies new markers of chemoresistance of triple-negative breast cancer. PLoS One. 2014;9:e96228. doi:10.1371/journal.pone.009622824788655
   PubMed Web of Science ®Google Scholar
• Bandres E, Cubedo E, Agirre X, et al. Identification by Real-time PCR of 13 mature microRNAs differentially expressed in colorectal cancer and non-tumoral tissues. Mol Cancer. 2006;5:29. doi:10.1186/1476-4598-5-2916854228
   PubMed Web of Science ®Google Scholar
• Wang CJ, Zhou ZG, Wang L, et al. Clinicopathological significance of microRNA-31, −143 and −145 expression in colorectal cancer. Dis Markers. 2009;26:27–34. doi:10.1155/2009/92190719242066
   PubMed Web of Science ®Google Scholar
• Laurila EM, Kallioniemi A. The diverse role of miR-31 in regulating cancer-associated phenotypes. Genes Chromosomes Cancer. 2013;52:1103–1113. doi:10.1002/gcc.v52.1223999990
   PubMed Web of Science ®Google Scholar
• Deftereos G, Corrie SR, Feng Q, et al. Expression of mir-21 and mir-143 in cervical specimens ranging from histologically normal through to invasive cervical cancer. PLoS One. 2011;6:e28423. doi:10.1371/journal.pone.002842322194833
   PubMed Web of Science ®Google Scholar
• Orang AV, Barzegari A. MicroRNAs in colorectal cancer: from diagnosis to targeted therapy. Asian Pac J Cancer Prev. 2014;15(17):6989–6999. doi:10.7314/APJCP.2014.15.17.698925227782
   PubMedGoogle Scholar
• Liu X, Zhao W, Wang X, Zhu Y, Zhou Z, Shi B. Expression of mir-143 in serum of bladder cancer patients and its correlation with clinical features and prognosis. J BU ON. 2019;24(2):791–796.
   PubMed Web of Science ®Google Scholar
• Zhang J, Ma D, Liu H, et al. MicroRNA-143 shows tumor suppressive effects through inhibition of oncogenic K-Ras in pituitary tumor. Int J Clin Exp Pathol. 2017;10(11):10969–10978.31966441
   PubMed Web of Science ®Google Scholar
• Johannessen C, Moi L, Kiselev Y, et al. Expression and function of the miR-143/145 cluster in vitro and in vivo in human breast cancer. PLoS One. 2017;12:e0186658. doi:10.1371/journal.pone.018665829073169
   PubMed Web of Science ®Google Scholar
• Akao Y, Nakagawa Y, Naoe T. MicroRNAs 143 and 145 are possible common onco-microRNAs in human cancers. Oncol Rep. 2006;16:845–850.16969504
   PubMed Web of Science ®Google Scholar
• Motoyama K, Inoue H, Takatsuno Y, et al. Over- and under-expressed microRNAs in human colorectal cancer. Int J Oncol. 2009;34:1069–1075. doi:10.3892/ijo_0000023319287964
   PubMed Web of Science ®Google Scholar
• Yan X, Chen X, Liang H, et al. miR-143 and miR-145 synergistically regulate ERBB3 to suppress cell proliferation and invasion in breast cancer. Mol Cancer. 2014;13:220. doi:10.1186/1476-4598-13-22025248370
   PubMed Web of Science ®Google Scholar